Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received approval from China’s National Medical Products Administration for a clinical trial of its innovative drug SKB501, designed to treat advanced solid tumors. This novel ADC drug, developed using the company’s OptiDC platform, has shown promising results in preclinical studies. Investors are advised to exercise caution as there is no guarantee of successful commercialization.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.